The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
Only 40% of Pediatric CNS Cancer Survivors Achieve Full Independence as AdultsAugust 15th 2018
Sixty percent of adult survivors of pediatric CNS tumors do not achieve full functional and social independence, according to results from a study conducted by researchers at St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center.
Dr. Youngblood on T-Cell Differentiation/Exhaustion in Pediatric CancerAugust 13th 2018
Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the impact of T-cell differentiation and exhaustion in pediatric cancer.
Dr. Chi Discusses Tazemetostat Trial in INI1-Negative Pediatric TumorsAugust 9th 2018
Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.
Dr. Bailey Discusses the Treatment of Pediatric Patients With SarcomaAugust 7th 2018
Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.
Dr. Baker on Integrating Palliative Care into Pediatric OncologyAugust 3rd 2018
Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses integrating palliative care into the treatment of pediatric oncology.
Dr. Wistinghausen on Developing Drugs for Children With CancerJuly 25th 2018
Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.
Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid TumorsJuly 23rd 2018
Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.
Dr. Bailey on Clinical Needs in Pediatric Patients With Bone SarcomaJuly 13th 2018
Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses clinical needs in pediatric patients with bone sarcoma.
Dr. Baker on Approaching Palliative Care for Children With CancerJuly 13th 2018
Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses approaching palliative care for children with cancer.
Expert Discusses Molecular Analysis and Treatment Options in Pediatric EpendymomaJuly 12th 2018
Santhosh A. Upadhyaya, MD, discusses how chemotherapy prior to radiation can improve cure rates, the importance of long-term follow-up in this patient population, and emerging research and treatment for pediatric ependymoma.
FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal CancerJuly 11th 2018
The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Dr. Link on Nelarabine in Newly Diagnosed T-Cell MalignanciesJuly 10th 2018
Michael Link, MD, Lydia J. Lee Professor in Pediatric Cancer, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology, discusses the randomized trial testing nelarabine in patients with T-cell malignancies.
Tisagenlecleucel Nears European Approval for DLBCL, ALLJune 29th 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
Expert Stresses Importance of End-of-Life Care in Pediatric OncologyJune 14th 2018
Justin N. Baker, MD, discusses the benefits of a holistic approach to end-of-life care in pediatric oncology, as well as the importance of teaching palliative care to the next generation of oncologists and hematologists.
FDA Approves Pembrolizumab for Relapsed/Refractory PMBCLJune 13th 2018
The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or those who have relapsed after 2 or more prior lines of therapy.
Dr. Patterson Discusses the Use of TKIs in Pediatric CMLJune 7th 2018
Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the use of tyrosine kinase inhibitors in the treatment of patients with chronic myeloid leukemia.
Entrectinib Demonstrates Early Activity in Pediatric Tumors
All 3 patients with targeted gene fusions responded to the multikinase inhibitor entrectinib, according to a phase I study in children and young adults with advanced, previously treated central nervous system tumors.
Dr. Wistinghausen Discusses Targeted Therapies for Pediatric NHLMay 31st 2018
Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma.
FDA Grants Frontline Eltrombopag Priority Review for Severe Aplastic AnemiaMay 31st 2018
The FDA has granted a priority review to a supplemental new drug application for eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a frontline treatment for patients with severe aplastic anemia.